Company
Avalo Therapeutics, Inc. (AVTX)
Standardized SEC financial data for Avalo Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001534120 · NASDAQ · Pharmaceutical Preparations.
Revenue growth (YoY)
-86.6%
Return on equity
-94.2%
ROIC
-69.8%
Free cash flow
-$51.5M
Debt / equity
0.18×
Current ratio
8.14×
EPS (diluted)
$-5.84
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.7M | $5.4M | $18.1M | $1.9M | $441K | $59K |
| Cost of revenue |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$40.5M | -$70.9M | -$26.8M | -$30.7M | -$49.1M | -$51.5M |
| Capital expenditures |
Get AVTX data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/AVTX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/AVTX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"